ArticleJBMR plus2025
The comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
When denosumab is discontinued, antiresorptive therapy is necessary to mitigate high bone turnover bone loss. While bisphosphonates have been investigated for this, alternatives have received less attention. In the Comparison of Alendronate and Raloxifene after Denosumab (CARD) randomized, controlled, open-label study, we previously reported alendronate better suppressed bone remodeling and maintained denosumab-induced areal BMD (aBMD) gains than raloxifene, though raloxifene maintained femoral neck aBMD and partially inhibited loss elsewhere. In this exploratory analysis, we now assess the comparative ability of these drugs to maintain denosumab-induced improvements in peripheral volumetric BMD (vBMD), microarchitecture, and estimated bone strength. CARD randomized 51 postmenopausal women (60-81y) at high fracture risk to receive denosumab 60-mg by subcutaneous injection every 6 mo for 12-mo followed by either 12-mo of oral alendronate (70 mg weekly,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.